Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Menu

    Incruse Ellipta

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 185,189Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 10Anoro Ellipta

    02 8Incruse Ellipta

    03 8Trelegy Ellipta

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Incruse Ellipta

    Umeclidinium, Vilanterol

    arrow
    ESCRS
    Not Confirmed

    Brand Name : Incruse Ellipta

    United Kingdom
    arrow
    ESCRS
    Not Confirmed

    GlaxoSmithKline

    Umeclidinium, Vilanterol

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2020 Revenue in Millions : 305

    2019 Revenue in Millions : 363

    Growth (%) : -16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Anoro Ellipta

    Umeclidinium, Vilanterol

    arrow
    ESCRS
    Not Confirmed

    Brand Name : Anoro Ellipta

    United Kingdom
    arrow
    ESCRS
    Not Confirmed

    GlaxoSmithKline

    Umeclidinium, Vilanterol

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2020 Revenue in Millions : 758

    2019 Revenue in Millions : 713

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Trelegy Ellipta

    Fluticasone Furoate, Vilanterol Trifenatate, Umeclidinium Bromide

    arrow
    ESCRS
    Not Confirmed

    Brand Name : Trelegy Ellipta

    United Kingdom
    arrow
    ESCRS
    Not Confirmed

    GlaxoSmithKline

    Fluticasone Furoate, Vilanterol Trifenatate, Umeclidinium Bromide

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2020 Revenue in Millions : 1,135

    2019 Revenue in Millions : 718

    Growth (%) : 58

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Anoro Ellipta

    Umeclidinium, Vilanterol

    arrow
    ESCRS
    Not Confirmed

    Brand Name : Anoro Ellipta

    United Kingdom
    arrow
    ESCRS
    Not Confirmed

    GlaxoSmithKline

    Umeclidinium, Vilanterol

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2021 Revenue in Millions : 682

    2020 Revenue in Millions : 749

    Growth (%) : -8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Incruse Ellipta

    Umeclidinium, Vilanterol

    arrow
    ESCRS
    Not Confirmed

    Brand Name : Incruse Ellipta

    United Kingdom
    arrow
    ESCRS
    Not Confirmed

    GlaxoSmithKline

    Umeclidinium, Vilanterol

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2021 Revenue in Millions : 277

    2020 Revenue in Millions : 301

    Growth (%) : -7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Trelegy Ellipta

    Fluticasone Furoate, Vilanterol Trifenatate, Umeclidinium Bromide

    arrow
    ESCRS
    Not Confirmed

    Brand Name : Trelegy Ellipta

    United Kingdom
    arrow
    ESCRS
    Not Confirmed

    GlaxoSmithKline

    Fluticasone Furoate, Vilanterol Trifenatate, Umeclidinium Bromide

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2021 Revenue in Millions : 1,647

    2020 Revenue in Millions : 1,122

    Growth (%) : 49

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Anoro Ellipta

    Umeclidinium, Vilanterol

    arrow
    ESCRS
    Not Confirmed

    Brand Name : Anoro Ellipta

    United Kingdom
    arrow
    ESCRS
    Not Confirmed

    GSK

    Umeclidinium, Vilanterol

    Main Therapeutic Indication : Respiratory Diseases

    Currency : USD

    2022 Revenue in Millions : 595

    2021 Revenue in Millions : 682

    Growth (%) : -13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Trelegy Ellipta

    Fluticasone Furoate, Vilanterol Trifenatate, Umeclidinium Bromide

    arrow
    ESCRS
    Not Confirmed

    Brand Name : Trelegy Ellipta

    United Kingdom
    arrow
    ESCRS
    Not Confirmed

    GSK

    Fluticasone Furoate, Vilanterol Trifenatate, Umeclidinium Bromide

    Main Therapeutic Indication : Respiratory Diseases

    Currency : USD

    2022 Revenue in Millions : 2,132

    2021 Revenue in Millions : 1,647

    Growth (%) : 29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Incruse Ellipta

    Umeclidinium, Vilanterol

    arrow
    ESCRS
    Not Confirmed

    Brand Name : Incruse Ellipta

    United Kingdom
    arrow
    ESCRS
    Not Confirmed

    GSK

    Umeclidinium, Vilanterol

    Main Therapeutic Indication : Respiratory Diseases

    Currency : USD

    2022 Revenue in Millions : 242

    2021 Revenue in Millions : 277

    Growth (%) : -13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Trelegy Ellipta

    Fluticasone Furoate, Vilanterol Trifenatate, Umeclidinium Bromide

    arrow
    ESCRS
    Not Confirmed

    Brand Name : Trelegy Ellipta

    United Kingdom
    arrow
    ESCRS
    Not Confirmed

    GSK

    Fluticasone Furoate, Vilanterol Trifenatate, Umeclidinium Bromide

    Main Therapeutic Indication : Respiratory Diseases

    Currency : USD

    2023 Revenue in Millions : 2,377

    2022 Revenue in Millions : 2,132

    Growth (%) : 27

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF